Building Optimal Three-Drug Combination Chemotherapy Regimens
暂无分享,去创建一个
W. Yamada | M. Neely | G. Drusano | S. Schmidt | C. Peloquin | A. Louie | Sarah Kim | Jocelyn Nole | Brandon Duncanson | Nino Mtchedlidze
[1] R. Nation,et al. In Pursuit of the triple Crown: mechanism-based pharmacodynamic modeling for the optimization of 3-drug combinations against KPC-Producing Klebsiella pneumoniae. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] G. Drusano,et al. Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay , 2018, Antimicrobial Agents and Chemotherapy.
[3] W. Yamada,et al. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model , 2018, Antimicrobial Agents and Chemotherapy.
[4] G. Drusano,et al. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay , 2018, Antimicrobial Agents and Chemotherapy.
[5] Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) , 2017, Scientific Reports.
[6] P. Converse,et al. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.
[7] L. Via,et al. An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions. , 2017, Journal of visualized experiments : JoVE.
[8] K. Kaye,et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity , 2017, The Journal of antimicrobial chemotherapy.
[9] G. Drusano,et al. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy , 2015, mBio.
[10] Matthew D. Zimmerman,et al. The association between sterilizing activity and drug distribution into tuberculosis lesions , 2015, Nature Medicine.
[11] A. Schumitzky,et al. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. , 2015, The Journal of infectious diseases.
[12] K. Mdluli,et al. Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[13] A. Schumitzky,et al. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis , 2014, PloS one.
[14] S. Mcleay,et al. Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug , 2014, Antimicrobial Agents and Chemotherapy.
[15] Alan Schumitzky,et al. Meropenem plus Levofloxacin is Synergistic for the Therapy of Pseudomonas aeruginosa as Tested in a Murine Model of Pneumonia , 2014 .
[16] Alan Schumitzky,et al. Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.
[17] K. Andries,et al. Pharmacokinetics and Pharmacodynamics of TMC207 and Its N-Desmethyl Metabolite in a Murine Model of Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.
[18] H. Derendorf,et al. PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.
[19] G. Drusano,et al. The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model , 2010, mBio.
[20] M. Laurenzi,et al. Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects , 2009, Antimicrobial Agents and Chemotherapy.
[21] V. Nandi,et al. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy , 2006, Antimicrobial Agents and Chemotherapy.
[22] V. Tam,et al. The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect Resistance , 2006, Antimicrobial Agents and Chemotherapy.
[23] A. MacGowan,et al. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. , 1999, Expert opinion on investigational drugs.
[24] Rory A. Fisher,et al. The Arrangement of Field Experiments , 1992 .
[25] Treatment of Pulmonary Tuberculosis with Streptomycin and Para-Amino-Salicylic Acid , 1950 .
[26] TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. , 1950, British medical journal.